echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Gale and Corning Jerry reached an exclusive global development agreement for PD-L1 antiviral indications

    Gale and Corning Jerry reached an exclusive global development agreement for PD-L1 antiviral indications

    • Last Update: 2022-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On November 8, Gerry Pharmaceuticals announced that its subsidiary and Corning Jerry had signed an exclusive global development agreement for ASC22 (Envolimab) to treat all viral diseases including hepatitis B outside of Greater China


    Under the terms of the agreement, Corning granted Jerry song ceremony outside Greater China and developed exclusive worldwide commercialization rights and interests of ASC22, indications for all viral diseases, including hepatitis B, including


    On January 14, 2019, Gale and Corning Jerry jointly announced that the two parties have reached an exclusive development agreement for ASC22 in Greater China


    On October 12 this year, Gallite Pharmaceuticals announced that it will orally report the results of the ASC22 chronic hepatitis B phase IIa study at the 2021 American Association for the Study of Liver Diseases (AASLD) annual meeting


    Currently, ASC22 is undergoing a phase IIb clinical trial in China


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.